ENTR-601-44 hit a functional endpoint at first dose — higher-dose readouts and a runway expiring Q3 2027 now determine whether this DMD platform survives to registrational data

Entrada is an early-stage company developing a gene therapy for Duchenne muscular dystrophy that is not yet approved, with a lead program that has shown functional improvement in initial patients but needs to demonstrate stronger results at higher doses to advance toward regulatory submission before its cash runs out.

Entrada's ENTR-601-44 became the first program in its cell-penetrating peptide exon-skipping platform to demonstrate statistically significant functional improvement in DMD patients, clearing a hurdle most early-stage oligonucleotide programs do not clear at Cohort 1. The thesis resolves on whether higher doses (12–18 mg/kg) produce a dystrophin response compelling enough for regulators to accept single-arm Phase 1/2 data as a registration package. Cash runway extends only to Q3 2027, leaving little margin if dose escalation data require additional cohorts before a filing decision.